F10 and intracerebral hemorrhage: All-cause mortality was 34%, with similar rates between the on- and off-label groups.<h4>Conclusion</h4>Andexanet alfa was primarily prescribed for the reversal of FXa inhibitors in patients with intracerebral hemorrhage.